{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-050925","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.924195+00:00","generated_at":"2026-06-10T06:19:38.899765+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Eledon Pharmaceuticals appoints Dr. Allan Douglas Kirk to board of directors","bullets":["Board expands from 8 to 9 directors; Dr. Kirk effective Oct 2, 2023.","Determined independent under Nasdaq rules; will serve on Science and Technology Committee.","Annual cash retainers: $42,000 for board service, $7,875 for committee service.","Granted option for 150,437 shares at market price on Oct 2, 2023; vests over 2 years.","Enters standard indemnification agreement for directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-050925","json":"https://secwatch.observer/filing/0000950170-23-050925.json","markdown":"https://secwatch.observer/filing/0000950170-23-050925.md","text":"https://secwatch.observer/filing/0000950170-23-050925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023050925/0000950170-23-050925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023050925/eldn-20230929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:19:38.899765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b973371c5","claim":"Allan Douglas Kirk was appointed as Director at Eledon Pharmaceuticals, Inc..","evidence_excerpt":"On September 29, 2023, Allan Douglas Kirk, MD, PhD, FACS, was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023050925/0000950170-23-050925-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}